May 27, 2020
Rebif® U.S. Label Now Includes Pregnancy Outcomes and Lactation Information to Help Inform Treatment Decisions for Women with MS
May 23, 2020
New Late-Breaking Data at EAN Indicate Evobrutinib is the First BTK Inhibitor to Report Efficacy and Safety in MS Over 108 Weeks
Apr 21, 2020
Multiple Sclerosis Drugs Industry Assessment 2020: Immunomodulators, Immunosuppressants, Interferons and Others
Mar 03, 2020
Novartis receives Health Canada approval for Mayzent(TM) (siponimod) to treat secondary progressive multiple sclerosis with active disease
Feb 27, 2020
Mallinckrodt to Present New Data from two Studies on Acthar® Gel (Repository Corticotropin Injection) Therapy in Multiple Sclerosis (MS) Relapse at Fifth Annual ACTRIMS Forum 2020
Feb 11, 2020
Overall Share of Ocrevus Remains Stable Among Recent New Start Patients, Yet Genentech's Efforts to Increase First-Line Use Appears to be Paying Off in the Dominant Relapsing-Remitting Multiple Sclerosis Subgroup
Feb 06, 2020
EMD Serono Receives Positive Recommendation for MAVENCLAD® (cladribine tablets) for the treatment of Relapsing-Remitting Multiple Sclerosis from the Institut national d'excellence en santé et en services sociaux (INESSS)
Jan 23, 2020
Multiple Sclerosis Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027
Jan 09, 2020
Clene Nanomedicine Announces First Patient Dosed in the REPAIR-MS Clinical Trial for the Treatment of Multiple Sclerosis with Lead Nanocatalytic Therapeutic, CNM-Au8
Jan 07, 2020
Clinical Trial of Autologous Hematopoietic Stem Cell Transplantation versus Best Available Therapy for Multiple Sclerosis (BEAT-MS) Begins Enrollment
Dec 10, 2019
EMD Serono and the pan-Canadian Pharmaceutical Alliance Complete Negotiations for MAVENCLAD® (cladribine tablets) for the treatment of Relapsing-Remitting Multiple Sclerosis
Nov 07, 2019
Mallinckrodt Announces Data Publication on the Treatment Effectiveness of Acthar® Gel (Repository Corticotropin Injection) for Resolution of Multiple Sclerosis Relapse in a U.S. Health Plan Population
Oct 31, 2019
Teva Canada Announces the Launch of a Bioequivalent Generic Version of [Pr]Gilenya®, [Pr]Teva-Fingolimod Capsules for the treatment of Relapsing-Remitting Multiple Sclerosis (MS)
Sep 13, 2019
Mallinckrodt Analysis Suggests Acthar® Gel (Repository Corticotropin Injection) May be a Cost-Effective Option Compared to Other Late-Line, Adult Treatments for Multiple Sclerosis Relapse
Aug 12, 2019
Medicines targeting multiple sclerosis and lymphoma are among new specialty drugs available through AllianceRx Walgreens Prime
Jul 30, 2019
Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared to Dimethyl Fumarate in Patients with Multiple Sclerosis
May 28, 2019
EMD Serono to Present Data at CMSC Annual Meeting Showcasing Breadth of MS Portfolio and Commitment to Understanding How MS Impacts Patients
May 28, 2019
EMD Serono's Mavenclad Edges Past Novartis' Gilenya in the Recent Switch Segment of Canada's Multiple Sclerosis Market, Although Brand Familiarity Remains An Addressable Barrier
May 10, 2019
Positive Phase II Data Further Highlights Clinical Proof of Concept for Evobrutinib, First Oral Bruton's Tyrosine Kinase (BTK) Inhibitor to Report Positive Phase II Clinical Results in MS
May 07, 2019
EMD Serono Launches MS-LINK(TM), a Community to Advance MS Science and Improve Patient Lives